<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343408</url>
  </required_header>
  <id_info>
    <org_study_id>I175</org_study_id>
    <secondary_id>CAN-NCIC-IND175</secondary_id>
    <secondary_id>CDR0000481443</secondary_id>
    <nct_id>NCT00343408</nct_id>
  </id_info>
  <brief_title>AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination With Selected Standard Chemotherapy Regimens (CT) in Patients With Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and&#xD;
      by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Giving AZD2171 together with standard combination chemotherapy may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of AZD2171 when given&#xD;
      together with standard combination chemotherapy in treating patients with advanced non-small&#xD;
      cell lung cancer (NSCLC) or colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the recommended phase II dose of AZD2171 when administered with standard&#xD;
           combination chemotherapy in patients with advanced non-small cell lung cancer or&#xD;
           colorectal cancer.&#xD;
&#xD;
        -  Determine the safety, tolerability, toxicity profile, dose-limiting toxicities, and&#xD;
           pharmacokinetic profile of this treatment regimen.&#xD;
&#xD;
        -  Assess the antitumor activity of this treatment regimen in patients with measurable&#xD;
           disease.&#xD;
&#xD;
        -  Correlate the toxicity profile with pharmacokinetics.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open-label, dose-escalation study of AZD2171. Patients are&#xD;
      assigned to 1 of 2 treatment groups according to disease.&#xD;
&#xD;
        -  Group 1 (non-small cell lung cancer): Patients receive gemcitabine hydrochloride IV on&#xD;
           days 1 and 8 and cisplatin IV on day 1. Patients also receive oral AZD2171 once daily&#xD;
           beginning on day 2. Treatment repeats every 21 days in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Group 2 (colorectal cancer): Patients receive oxaliplatin IV over 2 hours and leucovorin&#xD;
           calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days&#xD;
           1 and 2. Patients also receive oral AZD2171 once daily beginning on day 3. Treatment&#xD;
           repeats every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      In both groups, cohorts of 3-6 patients receive escalating doses of AZD2171 until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at&#xD;
      least 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks and then every 3 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2005</start_date>
  <completion_date type="Actual">September 22, 2008</completion_date>
  <primary_completion_date type="Actual">September 18, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">31</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cediranib maleate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Non-small cell lung cancer (NSCLC), meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Stage IIIB disease&#xD;
&#xD;
                         -  No pleural effusion and not a candidate for a combined modality&#xD;
                            treatment&#xD;
&#xD;
                    -  Stage IV disease&#xD;
&#xD;
                    -  Local or metastatic failure after surgery and/or radiotherapy&#xD;
&#xD;
               -  Colorectal cancer (CRC)&#xD;
&#xD;
                    -  Advanced and/or metastatic disease&#xD;
&#xD;
                    -  Suitable for first-line therapy with oxaliplatin, leucovorin calcium, and&#xD;
                       fluorouracil (FOLFOX-6)&#xD;
&#xD;
          -  Clinically or radiologically documented disease&#xD;
&#xD;
               -  No tumor marker elevation as sole evidence of disease&#xD;
&#xD;
          -  No necrotic/hemorrhagic metastases or tumor&#xD;
&#xD;
          -  No untreated brain or meningeal metastases&#xD;
&#xD;
               -  Previously treated, radiologic or clinical evidence of stable brain metastases&#xD;
                  allowed provided disease is asymptomatic and corticosteroids are not required&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Hemoglobin normal&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  AST or ALT ≤ 2 times ULN (5 times ULN if liver involvement)&#xD;
&#xD;
          -  Proteinuria ≤ grade 1&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of other malignancies except adequately treated nonmelanoma skin cancer or&#xD;
             other solid tumors curatively treated with no evidence of disease for ≥ 5 years&#xD;
&#xD;
          -  No untreated and/or uncontrolled cardiovascular conditions or symptomatic cardiac&#xD;
             dysfunction&#xD;
&#xD;
          -  No resting blood pressure (BP) consistently higher than systolic BP &gt; 150 mm Hg and&#xD;
             diastolic BP &gt; 100 mm Hg (in the presence or absence of a stable dose of&#xD;
             antihypertensive medication)&#xD;
&#xD;
          -  No poorly controlled hypertension, history of labile hypertension, or poor compliance&#xD;
             with antihypertensive medication&#xD;
&#xD;
          -  No overt bleeding (≥ 30 mL bleeding/episode) within the past 3 months&#xD;
&#xD;
          -  No clinically relevant hemoptysis (≥ 5 mL fresh blood) within the past 4 weeks&#xD;
&#xD;
               -  Flecks of blood in sputum allowed&#xD;
&#xD;
          -  No active or uncontrolled infections&#xD;
&#xD;
          -  No serious illnesses or medical conditions that would preclude compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  No mean QTc with Bazett's correction &gt; 470 msec&#xD;
&#xD;
          -  No history of familial long QT syndrome&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No dihydropyrimidine dehydrogenase deficiency or history of severe hand-foot syndrome&#xD;
             after fluoropyrimidines (for patients with CRC)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 6 months since prior adjuvant or neoadjuvant therapy&#xD;
&#xD;
          -  At least 6 months since prior adjuvant radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin C)&#xD;
             (for patients with NSCLC)&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent corticosteroids&#xD;
&#xD;
          -  At least 3 weeks since prior palliative radiotherapy and recovered&#xD;
&#xD;
               -  Concurrent palliative radiotherapy allowed&#xD;
&#xD;
          -  At least 2 weeks since prior epidermal growth factor receptor inhibitor therapy&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery&#xD;
&#xD;
          -  No more than 1 prior single-agent, nonplatinum-containing chemotherapy regimen for&#xD;
             metastatic disease (for patients with NSCLC)&#xD;
&#xD;
          -  No prior gemcitabine hydrochloride (for patients with NSCLC)&#xD;
&#xD;
          -  No prior oxaliplatin (for patients with CRC)&#xD;
&#xD;
          -  No prior angiogenesis inhibitor&#xD;
&#xD;
          -  No prior chemotherapy for advanced/metastatic disease (for patients with CRC)&#xD;
&#xD;
          -  No other concurrent experimental drugs or anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Batist, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jewish General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric X. Chen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Glenwood D. Goss, MD, BCh, FCP, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Ottawa Regional Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital - Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Chen E, Jonker D, Gauthier I, MacLean M, Wells J, Powers J, Seymour L. Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. Clin Cancer Res. 2009 Feb 15;15(4):1481-6. doi: 10.1158/1078-0432.CCR-08-0761.</citation>
    <PMID>19228749</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 22, 2006</study_first_submitted>
  <study_first_submitted_qc>June 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2006</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cediranib</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

